Age Related Macular Degeneration Clinical Trial
Official title:
Evaluation of Visual Function Impairments in Patients With Early Dry Age-related Macular Degeneration
The study hypothesis is that patients with dry age-related macular degeneration experience
visual function impairments such as defects in dark adaptation, glare intolerance, poor light
transition and reading in low lighting conditions. Studies have shown that patients in the
early phases of AMD with normal visual acuity commonly reported difficulty with these visual
functions but there have been no systematic studies evaluating these deficits in this
population.
This prospective, exploratory study will include up to 130 patients with dry AMD and 60
controls. These patients will undergo the following non-invasive visual function testing:
- microperimetry with eye tracking
- low luminance visual acuity
- specialized color vision (cone-specific)
- contrast testing and night vision testing.
High-resolution spectral domain optical coherence tomography (SDOCT) images will be taken of
the central retina using the Spectralis OCT unit. The values of visual function tested will
be correlated with the findings on SDOCT (volume/amount of drusen present in early AMD).
There are no known risks to the subjects beyond what is normal for standard examinations of
the eye, visual function testing and standard ocular photographic procedures.
This prospective, exploratory study will be performed in multiple arms:
A. Arm 1: a pilot study of up to 40 patients (30 patients with dry age-related macular
degeneration and 10 normal age-matched controls) in order to test 1) the feasibility of
performing the visual function tests in this population and 2) test/retest reliability over
1-2 months. If the pilot study reveals that the visual function tests proposed are feasible
and have high reliability, the larger study (Phase 2) will be subsequently performed.
B. Arm 2: a study of up to 160 patients (130 dry AMD patients and 32 controls) with the goal
of evaluating the changes in visual function in dry AMD as compared to age-matched control
subjects. Study will include patients determined on examination have dry AMD as well as
age-matched normal control subjects without dry AMD. If two eyes satisfy the inclusion
criteria, both eyes will be tested.
After consent is obtained following full explanation of the research, subjects will undergo
the following non-invasive visual function testing: dark adaptation microperimetry with eye
tracking, specialized color vision (cone specific), contrast testing and night vision
testing. During the standard retina examination, color fundus photos will be taken using a
Zeiss camera. Fundus Autoflorescence (FA), macular pigment optical density (MPOD) based on
blue- green dual wave lenght FAF and high resolution spectral domain OCT(SDOCT) images will
be taken of the central retina using the Heidelberg Spectralis OCT unit. The values of visula
function tested will be correlated with the findings on SDOCT (volume/amount of drusen
present in dry AMD).
During a testing day, the first patients first will undergo microperimetry testing, which
incorporates an eye tracker that operates independently of the microperimeter and is able to
compare results with a reference database of normal subjects. A Line Scanning Laser
Ophthalmoscope (SLO) is used to capture confocal images of the retina. Using the SLO image,
the operator can see the area to test. For follow-up examinations, the same area will be
tested and the machine generates a report on change from previous examination. The test takes
approximately 5 minutes.
Patients will then undergo cone specific vision testing. The cone contrast test (CCT) is a
computer-based color test that rapidly identifies type (red, green, or blue) and severity
(mild, moderate, and severe) of color deficiency, quantifies color performance, and allows
early detection of acquired color deficiency. The automated test takes approximately 5
minutes to complete for all three cone tones; studies have shown impairment in blue and green
cones in AMD. The system also provides tests for low contrast sensitivity night vision
(simulate low lighting conditions, with darker background).
Using computerized visual acuity charts, the patients will also be tested for day and night
glare and luminance. Using a dark adaptometer, the dark adaptation time will be measured.
Subjects will also complete a quality of life questionnaire (NEI VFQ) and a low luminance
questionnaire. The duration of each test can vary but typically lasts for 10-30 minutes.
A tube of blood about 5 ml will be collected from about 160 willing participants anytime
during their study enrollment. The collected blood sample will be used for genetics studies
associated with AMD. The samples will be stored here at the Duke Eye Center until all needed
samples are obtained. All samples will be sent to Hoffman La Roche AG PDGE Functional
Excellence, Biosample and Repository Management Evaluation of visual function impairments in
patients with early dry age-related macular degeneration Basel, Switzerland for genetic
testing.
Follow-up visual function testing will be performed at different time points depending on the
Arm of the study: at 1-2 months for Arm 1 and approximately 6, 12, 18 and 24 months for Arm 2
using the same protocol, based on standard of care clinic visits.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03963817 -
Snapshot Camera for AMD
|
||
Recruiting |
NCT04929756 -
Eye Movement Rehabilitation in Low Vision Patients
|
||
Completed |
NCT04779398 -
Association of MPOD Values With Blue Light.
|
||
Terminated |
NCT03275753 -
Visual Function Tests in Age-related Macular Degeneration
|
||
Recruiting |
NCT03609307 -
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
|
Phase 2/Phase 3 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Active, not recruiting |
NCT01943396 -
Treatment of AMD With Rheohemapheresis /RHF/
|
Phase 4 | |
Completed |
NCT00963339 -
Age-Related Macular Degeneration (AMD) - Usability Study
|
N/A | |
Completed |
NCT00376701 -
Combination Therapy for Age-Related Macular Degeneration.
|
Phase 2 | |
Terminated |
NCT00347165 -
Intravitreal Bevacizumab for Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00800995 -
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
|
Phase 3 | |
Completed |
NCT04689789 -
OCTA and Retinal Angiomatous Proliferation
|
||
Completed |
NCT02567604 -
Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
|
||
Completed |
NCT02173496 -
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
|
||
Recruiting |
NCT01991730 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients
|
N/A | |
Active, not recruiting |
NCT01657669 -
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
|
Phase 4 | |
Completed |
NCT00791570 -
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
|
Phase 1 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Completed |
NCT00413829 -
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
|
Phase 2 |